ADMA Biologics (NASDAQ:ADMA) Stock Rating Upgraded by Zacks Research

ADMA Biologics (NASDAQ:ADMA) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Wednesday, Zacks reports.

A number of other equities research analysts have also issued reports on ADMA. Mizuho reduced their price target on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Canaccord Genuity Group dropped their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

ADMA Biologics Stock Up 0.7%

ADMA Biologics stock opened at $9.58 on Wednesday. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $20.46. The stock’s fifty day simple moving average is $9.13 and its 200-day simple moving average is $10.31. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $2.15 billion, a P/E ratio of 13.69 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. During the same period last year, the business posted $0.14 earnings per share. ADMA Biologics’s revenue was up 2.0% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics will post 0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in ADMA Biologics in the 2nd quarter valued at approximately $321,037,000. State Street Corp boosted its position in shares of ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after acquiring an additional 35,614 shares during the last quarter. Sachem Head Capital Management LP grew its holdings in ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP increased its position in ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors increased its position in ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after purchasing an additional 3,383,559 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.